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Abstract
Background: Chronic kidney disease (CKD) is a common disorder associated with increased morbidity and
mortality. Primary care physicians (PCPs) care for the majority of pre-dialysis CKD patients; however, PCPs often do
not recognize the presence of CKD based on serum creatinine levels. Prior studies suggest that PCPs and
nephrologists deliver suboptimal CKD care. One strategy to improve disease awareness and treatment is estimated
glomerular filtration rate (eGFR) reporting. We examined PCP and nephrologist CKD practices before and after
routine eGFR reporting.
Methods: We conducted a retrospective cohort study of patients with CKD 3b-4 (eGFR < 45) seen at a university-
based, outpatient primary care clinic. Using a chi-square or Fisher’s exact test, we compared co-management rates,
renal protective strategies, CKD documentation, and laboratory processes of care in 274 patients and 266 patients
seen in a 6-month period prior to and following eGFR implementation, respectively.
Results: CKD co-management increased from 22.6% pre-eGFR to 48.5% post-eGFR (P < 0.0001). eGFR reporting did
not improve angiotensin converting enzyme inhibitor or angiotensin receptor blocker use or quantitative urinary
testing. However, non-steroidal anti-inflammatory drug avoidance (pre-eGFR 81.8% vs. post- eGFR 90.6%, P = 0.003)
and phosphorus and parathyroid hormone testing improved (pre-eGFR vs. post-eGFR: 32.5% vs. 51.5%, P < 0.0001;
12.4% vs. 36.1%, P < 0.0001 respectively).
Conclusions: A marked increase in CKD co-management was observed following eGFR implementation. Although
some improvements in processes of care were noted, this did not include angiotensin converting enzyme inhibitor
or angiotensin receptor blocker use. Overall care remained suboptimal despite eGFR reporting; further strategies
are needed to improve PCP and nephrologist CKD care.
Background
Over 12 million adults in the United States (US) have
chronic kidney disease (CKD) stage 3 or greater (estimated
glomerular filtration rate < 60 ml/min/1.73 m2) [1].
Further, the prevalence of CKD appears to be rising [1]
and with the increasing incidence of obesity, diabetes, and
hypertension [2-6], this trend is expected to continue. Pre-
sently, primary care physicians (PCPs) deliver most of the
care to patients with non-dialysis dependent CKD [7-10].
However, PCPs may not recognize the presence of CKD
and as many as 66% of PCPs may be unaware of Kidney
Disease Outcome Quality Initiative (K/DOQI) clinical
practice guidelines [11]. Given that CKD progression and
its associated morbidity and mortality can be reduced with
optimal care [12,13], late detection and treatment
contributes to poor patient outcomes [14]. Among the
approaches advocated for the improvement of CKD out-
comes are optimization of care by increasing disease
awareness and adherence to CKD clinical practice guide-
lines including angiotensin converting enzyme inhibitor
(ACEI) or angiotensin receptor blocker (ARB) use and
timely renal referrals.
One important development in the ongoing effort to
improve CKD recognition is the implementation of rou-
tine eGFR reporting. Although imperfect, eGFR values
account for demographic factors that are important
determinants of muscle mass and serum creatinine levels
and provide physicians with more accurate estimates of
kidney function than isolated serum creatinines [15]. The
National Kidney Foundation has advocated for the use of
prediction equations to estimate kidney function [16] and
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the most widely used equation is presently the 4-variable
Modification of Diet in Renal Disease (MDRD) Study
equation [17-21]. The routine reporting of eGFR values
with serum creatinine has been advocated by some
experts as an important approach to improve CKD
awareness and treatment [22-24] and recent data reveal
that an increasing number of US labs are adopting uni-
versal eGFR reporting [21,25]. Multiple studies have
documented the effect of routine eGFR reporting on
renal referrals [8,26-28]; however, few studies have exam-
ined the quality of care delivered to CKD patients since
the implementation of eGFR reporting [28-30]. In addi-
tion, despite previously well-documented deficiencies in
nephrologist care of CKD patients [10,31-35], few studies
have examined whether there have been improvements
in the care of co-managed CKD patients following eGFR
reporting.
In this report, we examine the care of patients with
advanced CKD (stages 3b-4) before and after routine
eGFR reporting at an academic, hospital-based primary
care (general internal medicine [GIM]) practice. In addi-
tion, we examine the care of advanced CKD patients
solely managed by their PCPs (hereafter referred to as
PCP managed) or co-managed with a nephrologist
(hereafter referred to as co-managed) before and after
routine eGFR reporting. We hypothesized that following
routine eGFR implementation there would be modest
improvements in care for PCP managed patients but no
improvements in care for co-managed patients. We also
hypothesized that co-managed CKD patients would have
better kidney-disease specific processes of care com-
pared to PCP managed patients.
Methods
Study population and setting
We conducted a retrospective review of University of
Pittsburgh Medical Center outpatients cared for at a
hospital-based primary care (i.e., GIM) clinic prior to
and following routine laboratory implementation of
eGFR reporting that began in October 2005. The study
inclusion criteria were age ≥ 18 years, the presence of at
least one automated or investigator-calculated eGFR
value of < 45 ml/min/1.73 m2, and an outpatient visit
with a university GIM PCP either during the 6-months
immediately prior to local laboratory eGFR reporting
(pre-eGFR cohort 4/1/05-9/30/05) or during 6-months
after local eGFR reporting had become routine (post-
eGFR cohort 12/1/07-5/31/08, Figure 1). We chose a
more recent 6-month post-eGFR period to allow the
measure to gain wider acceptance and to give providers
the opportunity to acclimate to its use. Participants
were excluded for the following reasons: prior kidney
transplant, any form of renal replacement therapy, CKD
stage 5 (eGFR < 15 ml/min/1.73 m2), or any automated
or investigator calculated eGFR ≥ 60 ml/min/1.73 m2.
The University of Pittsburgh Institutional Review Board
approved this study.
Data collection
Creatinine/eGFR ascertainment and reporting
For all eligible participants, all creatinine and eGFR
values were abstracted from the electronic medical
record (EMR). For the pre-eGFR cohort, all serum crea-
tinine values from 9/30/03 - 9/30/05 were abstracted.
For the post-eGFR cohort, all eGFR and serum creati-
nine values from 5/31/06 - 5/31/08 were abstracted.
Non-calibrated, modified Jaffe serum creatinine assays
were used by the local university laboratory during both
study periods. The 4-variable MDRD study equation
[18] was used by either the study investigators or the
local laboratory to calculate eGFR values for the pre-
eGFR cohort and the post-eGFR cohort, respectively.
For all patients with a laboratory reported eGFR, the
following message accompanied their eGFR results,
“eGFR < 60 mL/min/1.73 m2 indicates kidney disease.
eGFR < 15 mL/min/1.73 m2 indicates kidney failure.”
No systematic educational activities regarding eGFR
reporting were undertaken at the university hospital
prior to or following eGFR implementation as of 5/31/
2008.
Outcomes
The primary outcome was referral to a nephrologist
determined by the presence of an EMR order for a
nephrology consultation (regardless of whether the
patient kept the appointment) or the presence of a
nephrology encounter in the EMR during the six month
cohort period or within 2 months of the end of each
respective cohort period. This 2-month delay allowed
Pre-eGFR Cohort: 
seen by PCP between 
 4/1/05 - 9/30/05 
(n=9,082) 
Post-eGFR Cohort: 
seen by PCP between 
12/1/07 - 5/31/08 
(n=9,485) 
Excluded
x no creatinine from 
5/31/06 - 5/31/08 
(n=2,699) 
x History of KTx 
(n=53) 
x All eGFR > 45 
(n=6,284) 
Excluded
x no creatinine from 
9/30/03 - 9/30/05 
(n=3,388) 
x History of KTx 
(n=37) 
x All eGFR > 45 
(n=5,266) 
Investigator calculated eGFR < 45
(n= 391) 
Automated eGFR < 45 
 (n= 449) 
Excluded for any 
x eGFR > 60
(n=153) 
x eGFR < 15 
(n=30)
Excluded for any 
x eGFR > 60
(n=85) 
x eGFR < 15  
(n=32)
CKD 3b-4 
Co-managed 
(n=52) 
CKD 3b-4 
PCP managed 
(n=222) 
CKD 3b-4 
PCP managed
(n=159) 
CKD 3b-4 
Co-managed 
(n=107) 
Figure 1 Patient selection. eGFR estimated glomerular filtration
rate, KTx kidney transplant, CKD chronic kidney disease, PCP primary
care physician.
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time for patients evaluated at the end of the 6-month
period to have laboratory tests completed and further
orders placed (e.g., specialist referral) as deemed appro-
priate by the PCP.
Secondary outcomes included CKD documentation,
ACEI or ARB use, non-steroidal anti-inflammatory drug
(NSAID) use, urinary albumin quantification, and lab
monitoring of hemoglobin (Hgb), phosphorus, and para-
thyroid hormone (PTH) levels. We also intended to assess
serum calcium monitoring; however, in early 2006 serum
calcium was included in the laboratory’s basic metabolic
profile confounding any possible pre-eGFR versus post-
eGFR comparisons. CKD documentation was determined
by the presence of an International Classification of Dis-
ease, Ninth Revision (ICD-9) code on the patient’s EMR
problem list or as a billing diagnosis in a PCP outpatient
encounter. These codes included: 249.4(×), 250.4(×), 403.
(×), 404.(×), 581.(×), 582.(×), 585.(×), 586, 587, 588.(×),
593.7×, 753.13, 753.14, and 794.4. Use of an ACEI/ARB
was determined by the presence of an ACEI/ARB on the
patient’s EMR medication list at the end of each cohort
period. The EMR medication list automatically updates
based on electronic prescriptions or medications entered
for documentation purposes. Use of an NSAID was deter-
mined by the presence of an NSAID on the patient’s EMR
medication list at the end of each respective cohort period.
Urinary albumin quantification was determined by the
presence of an EMR order or laboratory value for a ran-
dom, quantitative spot assessment for albuminuria in the
prior 12 months. Lab testing for Hgb, phosphorus, and
PTH was determined by the presence of an EMR order or
laboratory value for each respective test within the prior
12 months.
Covariates
We abstracted the following covariates from the EMR on
all eligible patients: age, sex, race (self-reported), insur-
ance status, diagnosis of diabetes, diagnosis of hyperten-
sion, and baseline co-management status (i.e., baseline
renal referral status). Insurance status was categorized as
private, Medicare, medical assistance/Medicaid, or self-
pay. Diabetes and hypertension were determined by the
presence of the disease on the patient’s EMR problem list
or as a billing diagnosis in a PCP outpatient encounter in
the 12 months preceding the end of each cohort period.
Baseline co-management status was determined by the
presence of any EMR outpatient encounter with a
nephrologist during the 24 months preceding each
cohort period. A simple random sample was used to
select 10% of patient charts for an EMR chart audit to
verify the accuracy of abstracted data.
Statistical analyses
Differences between the groups in demographic charac-
teristics and clinical variables were assessed using a
Student’s t-test or analysis of variance for continuous
variables and a chi-square or Fisher’s exact test for cate-
gorical variables. Differences in clinical care (nephrology
referral, CKD documentation, ACEI/ARB use, etc) were
assessed using a chi-square or Fisher’s exact test for cate-
gorical variables. For the primary outcome (nephrology
referral), associations with demographic and clinical vari-
ables were assessed in the pre- and post-eGFR cohorts
using a chi-square test. Multivariable associations
between the dependent variable, co-management status,
and demographic and clinical variables were examined in
each cohort using a logistic regression model. Model
selection was based on variables that were found to have
an association (P < 0.2) in univariate analyses. Final
model variables were age, sex, race, insurance status, dia-
betic status, and creatinine. For all analyses, P values
< 0.05 were considered significant. Analyses were per-
formed using SAS version 9.1 (Cary, NC).
Results
Baseline characteristics
In the pre-eGFR cohort, 391 eligible patients had an
eGFR < 45 ml/min/1.73 m2 (Figure 1). Just over 79% of
these patients had 2 or more serum creatinine measure-
ments. In the post-eGFR cohort, 449 eligible patients
had an eGFR < 45 ml/min/1.73 m2 (Figure 1). Over 94%
had 2 or more serum creatinine measurements. After
excluding patients with any eGFR < 15 ml/min/1.73 m2
or ≥ 60 ml/min/1.73 m2, 274 and 266 patients remained
in the pre-eGFR and post-eGFR cohorts, respectively
(Figure 1).
Patients in the post-eGFR cohort were more likely to
be male, African-American, and have hypertension docu-
mented in the EMR than pre-eGFR patients (Table 1).
Additionally, post-eGFR patients were more likely to
have private insurance and less likely to have Medicare;
they also had higher serum creatinines and modestly
lower eGFR values (Table 1).
When examining patients stratified by eGFR cohort
and referral status (Table 2), PCP managed patients in
the pre-eGFR cohort were older, less likely to be Afri-
can-American, less likely to have hypertension docu-
mented in the EMR, less likely to have private insurance
and more likely to have Medicare than PCP managed
patients in the post-eGFR cohort. PCP managed patients
in the pre-eGFR cohort also had modestly lower serum
creatinines and higher eGFR values than PCP managed
post-eGFR patients.
Co-managed patients in the pre-eGFR cohort were
less likely to have hypertension documented in the EMR
than co-managed post-eGFR patients (Table 2).
Pre-eGFR PCP managed patients were significantly
older than pre-eGFR co-managed patients (Table 2). In
addition, PCP managed patients had lower serum
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creatinines and higher eGFR values than co-managed
patients regardless of their eGFR cohort.
Renal referrals and co-management
The overall prevalence of CKD 3b-4 co-management
increased significantly from the end of the pre-eGFR
cohort (22.6%) to the end of the post-eGFR cohort
(48.5%, P < 0.0001; Figure 2). Differences in the
prevalence of co-managed patients were apparent in
both the CKD 3b and CKD 4 subgroups (Figure 2). In
addition, a smaller proportion of PCP managed patients
were newly referred during the 8 month study/follow-up
period in the pre-eGFR cohort versus the post-eGFR
cohort; however, the absolute percentage of patients
newly referred was modest in both arms (pre-eGFR
4.5% vs. post-eGFR 13.8%, P = 0.001). The percentage of
patients newly referred to a nephrologist during the
study period was mildly higher when examining the
CKD 4 subgroup (pre-eGFR 9.4% [n = 32] vs. post-
eGFR 25.8% [n = 31], P = 0.09). Excluding all patients
with a single creatinine value did not substantially alter
our findings. Examining only patients with 3 or more
serum creatinine values did not qualitatively alter our
findings although a modest increase in co-management
was noted in both the pre-eGFR and post-eGFR groups.
We examined univariate associations with renal referral
status at the end of each cohort period. In the pre-eGFR
cohort, age < 70 (35% vs. 15%, P < 0.0001), African-
American race (34% vs. 19%, P = 0.01), and CKD docu-
mentation in the EMR (50% vs. 9%, P < 0.0001) were
associated with increased renal referrals. In the post-
eGFR cohort, male gender (57% vs. 43%, P = 0.03),
diabetic status (57% vs. 44%, P = 0.03), and CKD docu-
mentation in the EMR (79% vs. 17%, P < 0.0001) were
associated with increased referrals.
After adjusting for serum creatinine, a multivariable ana-
lysis of referral status revealed that only age < 70 years was
Table 1 Baseline characteristics
Pre-eGFR
(n = 274)
Post-eGFR
(n = 266)
P-Value*
Age (years) 70.5 (13.7) 68.7 (13.4) 0.12
Female 70.8% (194) 60.9% (162) 0.02
African-American 23.7% (65) 38.3% (102) 0.0002
Diabetes 31.8% (87) 36.8% (98) 0.21
Hypertension 63.1% (173) 79.7% (212) < 0.0001
Insurance Status
Private 32.5% (89) 46.6% (124) 0.002
Medicare 56.6% (155) 45.9% (122)
Medical Assistance 5.5% (15) 5.6% (15)
Self-pay 5.5% (15) 1.9% (5)
eGFR (ml/min/1.73 m2) 36.1 (7.1)** 33.7 (7.9)‡ 0.0002
Creatinine (mg/dl) 1.80 (0.52)** 1.97 (0.72)‡ 0.002
Continuous variables are presented as means with standard deviations.
Categorical variables are expressed as percentages and frequencies.
*Students t-test, chi-square, or Fisher’s exact test used as appropriate.
eGFR estimated glomerular filtration rate.
Table 2 Baseline characteristics by eGFR and co-managed status
Pre-eGFR/ PCP
managed
(n = 222)
Post-eGFR/ PCP
managed
(n = 159)
P-Value* (PCP
managed,
Pre vs. Post)
Pre-eGFR/
Co-managed
(n = 52)
Post-eGFR/
Co-managed
(n = 107)
P-Value* (Co- managed,
Pre vs. Post)
Age (years) 72.2 (12.5)† 69.6 (13.0) 0.05 63.3 (16.1)† 67.3 (14.0) 0.11
Female 72.1% (160) 62.9% (100) 0.06 65.4% (34) 57.9% (62) 0.37
African-American 22.5% (50) 36.5% (58) 0.0005 28.9% (15) 41.1% (44) 0.13
Diabetes 30.2% (67) 34.0% (54) 0.25 38.5% (20) 41.1% (44) 0.75
Hypertension 64.4% (143) 75.5% (120) 0.02 57.7% (30) 86.0% (92) < 0.0001
Insurance Status
Private 30.6% (68) 45.3% (72) 0.009 40.4% (21) 48.6% (52) 0.67
Medicare 59.0% (131) 49.1% (78) 46.2% (24) 41.1% (44)
Medical
Assistance
5.0% (11) 4.4% (7) 7.7% (4) 7.5% (8)
Self-pay 5.4% (12) 1.3% (2) 5.8% (3) 2.8% (3)
eGFR
(ml/min/1.73 m2)
37.2 (6.3)** 35.5 (7.5)‡ 0.02 31.4 (8.2)** 31.0 (7.6)‡ 0.78
Creatinine (mg/dl) 1.71 (0.42)** 1.83 (0.56)‡ 0.02 2.18 (0.71)** 2.19 (0.86)‡ 0.94
Continuous variables are presented as means with standard deviations. Categorical variables are expressed as percentages and frequencies.
*Students t-test, chi-square, or Fisher’s exact test used as appropriate.
†pre-eGFR PCP managed versus pre-eGFR co-managed (P = 0.0004).
**pre-eGFR PCP managed versus pre-eGFR co-managed (P < 0.0001).
‡post-eGFR PCP managed versus post-eGFR co-managed (P < 0.0001).
eGFR estimated glomerular filtration rate, PCP primary care physician.
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associated with renal referrals in the pre-eGFR cohort
while only diabetic status was borderline associated with
referrals in the post-eGFR cohort (Table 3). CKD docu-
mentation was excluded from these models due to con-
cern that nephrologists may have been responsible for
documenting CKD in the EMR problem list after a patient
was referred and evaluated.
Trends in CKD care
Overall, ACEI/ARB use, urinary albumin quantification,
absence of both ACEI/ARB and urinary albumin quantifi-
cation, and Hgb monitoring did not improve following
eGFR reporting (58.4% vs. 58.6%, P = 0.9; 24.5% vs.
29.3%, P = 0.2; 37.6% vs. 32.7%, P = 0.2; 80.3% vs. 86.1%,
P = 0.07, respectively). However, NSAID avoidance and
phosphorus and PTH monitoring improved following
routine eGFR reporting (81.8% vs. 90.6%, P = 0.003;
32.5% vs. 51.5%, P < 0.0001; 12.4% vs. 36.1%, P < 0.0001,
respectively). In sensitivity analyses examining patients
with at least 2 or at least 3 serum creatinine values, find-
ings did not substantially differ.
When examining PCP managed patients, there was no
difference in CKD documentation, ACEI/ARB use, urin-
ary albumin quantification, absence of ACEI/ARB and
urinary albumin quantification, or Hgb monitoring fol-
lowing the use of eGFR reporting (Figure 3 and Figure 4).
However, there was a borderline significant decrease in
NSAID use and significant improvements in phosphorus
and PTH monitoring following eGFR implementation
(Figure 3 and Figure 4).
When examining co-managed patients, only PTH mon-
itoring improved following eGFR reporting (Figure 3 and
Figure 4). However, ACEI/ARB use in co-managed CKD
4 patients rose from 36.4% (n = 22) pre-eGFR to 60.5%
(n = 43) post-eGFR, although this was not statistically
significant (P = 0.07).
When comparing PCP managed and co-managed
patients, NSAID use was higher and phosphorus and
PTH monitoring were lower in PCP managed patients
regardless of eGFR reporting (Figure 3 and Figure 4). In
addition, in the post-eGFR cohort, PCP managed
patients were less likely to obtain Hgb testing than co-
managed patients (Figure 4).
Discussion
We observed a substantial increase in CKD patient co-
management following the use of routine eGFR reporting
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Figure 2 Co-management of CKD patients by eGFR cohort. Pre-
eGFR cohort: N=274, Post-eGFR cohort: N=266 *P<0.0001, †P=0.01
CKD chronic kidney disease, eGFR estimated glomerular filtration
rate
Table 3 Multivariable associations with co-managed
status after adjusting for serum creatinine
Pre-eGFR
cohort*
Post-eGFR
cohort†
Adjusted OR
(95%CI)
Adjusted OR
(95%CI)
Age (< 70 vs. ≥ 70 years) 2.74 (1.37-5.49) 1.49 (0.84-2.66)
Sex (female vs. male) 1.48 (0.65-3.36) 0.99 (0.54-1.84)
Race (AA vs. non-AA) 1.05 (0.49-2.27) 0.85 (0.47-1.55)
Insurance Status (private vs. non-
private**)
1.81 (0.88-3.76) 1.16 (0.65-2.07)
Diabetes (diabetic vs. non-
diabetic)
1.61 (0.81-3.19) 1.77 (1.00-3.14)
For each variable, the referent is the latter value listed within parentheses.
*Pre-eGFR cohort: N = 274;
†Post-eGFR cohort: N = 266;
**Non-private insurance included Medicare, medical assistance/Medicaid, or
self-pay.
eGFR estimated glomerular filtration rate, AA: African-American.
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Figure 3 Quality of care delivered to CKD 3b-4 patients .
Pre-eGFR cohort: n=274, Post-eGFR cohort: n=266. † Pre-eGFR/PCP
vs. Post-eGFR/PCP, P=0.07; Pre-eGFR/PCP vs. Pre-eGFR/Co, P=0.01;
PosteGFR/ PCP vs. Post-eGFR/Co, P=0.003. CKD chronic kidney
disease documentation, ACEI/ARB angiotensin converting enzyme
inhibitor or angiotensin receptor blocker use, NSAID non-steroidal
anti-inflammatory drug, Ualb quantitative urinary albumin testing,
eGFR estimated glomerular filtration rate, PCP primary care physician
managed, Co co-managed.
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at an academic, hospital-based GIM clinic. At the conclu-
sion of the respective study periods, nearly 50% of CKD
3b-4 patients were co-managed in the post-eGFR cohort
compared to less than 25% of the pre-eGFR cohort. Sig-
nificant increases in co-management were apparent in
both CKD 3b and CKD 4 patients. Following eGFR
implementation, we also noted significant improvements
in NSAID avoidance and mineral and bone disease
related lab testing. However, ACEI/ARB use and urinary
albumin quantification were not improved. While CKD
care delivery to both PCP managed and co-managed
patients remained suboptimal after eGFR reporting, co-
managed patients were less likely to be on NSAIDs and
more likely to have lab testing for complications of CKD.
Our observed increase in CKD patient co-management
is similar to previous reports documenting increased
nephrology referrals following implementation of routine
eGFR reporting [8,26-28]. At our institution, moderate to
advanced CKD patients previously had their kidney dis-
ease managed predominantly by their PCPs. Now, nearly
half of all CKD 3b-4 patients are being co-managed. We
noted both an increase in the prevalent proportion of
CKD 3b-4 patients who were co-managed at the outset
of each cohort as well as a significant increase in the pro-
portion of patients who were newly referred during the
study period. Together, these increases in renal referrals
represent a substantial shift in CKD care by PCPs. Such
shifts in PCP practice patterns may pose a logistical chal-
lenge to nephrology groups that are not equipped to deal
with an influx of pre-dialysis CKD patients. Other centers
have successfully adopted education and referral guideline
programs to address this problem when present [8,36].
However, in localities where the increase in CKD patient
referrals does not overwhelm capacity, this shift provides
nephrologists with an opportunity to enhance the care of
many CKD patients at an earlier stage of disease when
treatment is more likely to prevent or delay cardiovascu-
lar disease and kidney failure [16,37-39].
Increased CKD co-management should lead to a greater
emphasis on ensuring that treatment delivered by PCPs
and nephrologists represents optimal care to reduce CKD
morbidity and mortality. In addition to improved commu-
nication between PCPs and nephrologists, important goals
in the management of CKD patients include blood pres-
sure control, proteinuria suppression, ACEI/ARB therapy,
cardiovascular disease risk factor modification, nephro-
toxin avoidance, and treatment of complications from
CKD (e.g., anemia) [7,40-42]. Although we did not exam-
ine clinical outcomes in this study, it is notable that ACEI/
ARB use and lack of both albuminuria screening and
ACEI/ARB therapy were unaffected by eGFR reporting.
While a trend towards improved ACEI/ARB use was seen
in co-managed CKD stage 4 patients, we suspect this was
due to recent literature documenting the safety and effi-
cacy of ACEI treatment in the setting of advanced CKD
that was not available during the pre-eGFR cohort [43].
Our findings are similar to previous studies reporting
minimal or no improvement in ACEI/ARB use following
eGFR implementation [28,29]. In addition, approximately
1/3 of our CKD cohort received neither an albuminuria
screen nor ACEI/ARB therapy. Hence, providers did not
know whether a significant number of their CKD patients
possessed characteristics making them likely to benefit
from ACEI/ARB therapy nor were they presumptively
treating such patients. Although contraindications to
ACEI/ARB therapy (e.g., angioedema, severe hyperkale-
mia) may have precluded their use, it should be noted
that published rates of hyperkalemia in a recent non-
dialysis dependent CKD 3-5 cohort were approximately
5-12% [44] and the approximate rate of hyperkalemia
(K > 5.5) for outpatients with CKD 3b-5 at our medical
center is 17.1% in the previous 12 months (unpublished
data). Hence, contraindications to ACEI/ARB are unlikely
to explain these shortcomings in care fully.
While differences in CKD care between PCP managed
and co-managed patients were apparent in the rates of
NSAID avoidance and lab monitoring for potential
complications of CKD, our findings generally confirm
studies documenting sub-optimal CKD care among
PCPs and nephrologists prior to eGFR reporting
[10,33-35,45]. These results suggest that even with
eGFR reporting, there remains substantial room for
improvement in CKD care. Despite the marked increase
in co-management, the majority of patients who were
PCP managed at the outset of each cohort were not
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Figure 4 Laboratory processes of care for CKD 3b-4 patients.
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referred over the subsequent 8-months. This is similar
to findings by Richards et al [8] who noted that despite
the marked increase in renal referrals following eGFR
implementation, only 33% of non-referred CKD 4-5
patients were referred in the following 12 months. This
implies that although referrals have generally increased
following eGFR reporting, a subset of patients may still
be referred late. In our multivariable adjusted model of
co-management status following eGFR reporting, only
creatinine and diabetic status were associated with
co-management. Given the documented increase in
morbidity and mortality associated with late referrals
[46], future studies should further examine patient char-
acteristics that are associated with late referrals despite
eGFR reporting.
Our findings should be interpreted in light of several
limitations. First, we only examined patients with a
documented creatinine value; however, some patients
with CKD 3b-4 are unscreened and would be excluded
from our analysis. Hence, the true rate of co-manage-
ment and appropriate process of care outcomes is likely
to be lower than reported here. Second, we required
one eGFR < 45 ml/min/1.73 m2 for inclusion in this
study. However, the current National Kidney Founda-
tion CKD definition requires a reduction in the GFR to
< 60 ml/min/1.73 m2 for at least 3 months. This poten-
tially resulted in misclassification. However, the pre-
sence of two or more calculated eGFR values in nearly
80% and 95% of patients in the pre-eGFR and post-
eGFR cohorts respectively and the exclusion of all
patients with a recent eGFR ≥ 60 ml/min/1.73 m2
should have minimized this bias. Further, exclusion of
patients with only 1 or 2 creatinine/eGFR measures did
not significantly alter our findings. Third, serum creati-
nine assays were not standardized during the study per-
iod. Fourth, there were additional important process of
care outcomes that we did not assess including appro-
priate lab monitoring following the initiation of ACEI/
ARB therapy. Fifth, improvements in care could be due
to secular trends rather than eGFR implementation. For
example, the recent interest in mineral and bone disease
including vitamin D deficiency could explain the
increased monitoring of phosphorus and PTH. In addi-
tion, there are other critical factors that may contribute
to differences in the care delivered to CKD patients that
were not controlled for in this study (e.g., patient
comorbidities, underlying etiology of CKD). Finally, we
studied a relatively small sample.
Conclusions
Following the implementation of routine eGFR reporting
at an academic, outpatient primary care clinic, there has
been a marked increase in the co-management of CKD
3b-4 patients and modest to moderate improvement in
CKD processes of care including NSAID avoidance and
mineral and bone disease related lab testing. However,
pre-dialysis CKD care remains suboptimal. While the
best approach to improve clinical care for CKD patients
is unproven, multiple interventions will likely be
required to affect physician behavior [47]. Simple educa-
tional didactics, printed materials, and guideline devel-
opment alone have generally failed to change practice
patterns in a variety of medical settings [47]. Alternative
approaches including combinations of audit and feed-
back, educational outreach, and clinical decision support
systems have garnered increasing attention as potentially
effective tools to improve physician performance
[48-53].
This study identifies not only PCP care as suboptimal,
but also reinforces prior documented shortcomings in
nephrology care [10,33-35,45]. Such deficiencies despite
the presence of CKD guidelines and eGFR reporting,
especially in an academic setting where patient visits are
generally longer and providers less hurried, highlight the
need to employ a conceptual model of suboptimal CKD
care delivery by providers to direct the evaluation of
further interventions that may improve care delivery.
Such a model should identify the numerous hurdles
including perceptual and interpretive errors that may
have been addressed by eGFR reporting. It should also
identify additional barriers including gaps in knowledge
and cognitive burdens not addressed by eGFR reporting
but that will need to be overcome to incrementally
enhance CKD care. Further studies are needed to
explore the role of systematic interventions in addres-
sing these barriers and optimizing the care of pre-dialy-
sis CKD patients.
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